NovoCure Limited (BUL:038)
Bulgaria · Delayed Price · Currency is EUR | Market Cap | 1.24B +8.2% |
| Revenue (ttm) | 638.78M +12.9% |
| Net Income | -107.20M |
| EPS | -0.96 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 10.91 |
| Day's Range | n/a |
| 52-Week Range | 10.77 - 12.87 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 25, 2027 |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim... [Read more]
Financial Performance
In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.
Financial numbers in USD Financial StatementsNews
Novocure announces publication of data analysis from Phase 3 PANOVA-3 trial
Novocure (NVCR) announced that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy concomitant with…
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial ...
Novocure price target raised to $31 from $27 at Ladenburg
Ladenburg raised the firm’s price target on Novocure (NVCR) to $31 from $27 and keeps a Buy rating on the shares following the FDA not approvable letter for Optune Mya.
Novocure receives Not Approvable Letter from FDA for PMA app for Optune Mya
Novocure (NVCR) announced that it has received a Not Approvable Letter from the U.S. Food and Drug Administration, FDA, in response to its Premarket Approval, PMA, application for Optune Mya…
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket A...
Novocure price target lowered to $20 from $23 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $20 from $23 and keeps an Outperform rating on the shares.
Novocure’s Pax disrupted by Revolution rollout, says Wedbush
Wedbush notes that active patients on Novocure’s (NVCR) Optune Pax declined to 276 in Q3 from 285 in Q2, reporting that management cited disruption from the introduction of Revolution Medicines’…
NovoCure Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $193M, up 16% YoY, and adjusted EBITDA was positive $16M. 2026 revenue and adjusted EBITDA guidance rose, while U.S. Pax uptake faced practice-access headwinds and Japan Lua continued to grow.
NovoCure Earnings release: Q3 2026
NovoCure released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
NovoCure Slides: Q3 2026
NovoCure has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Novocure reports Q3 EPS (9c), consensus (23c)
Reports Q3 revenue $193.4M, consensus $182.23M. “Novocure’s (NVCR) strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products laun...
Novocure raises FY26 revenue view $736M-$743M from $710M-$725M
Consensus $726.12M. Adjusted EBITDA: $24M – $34M, previous: $0M – $15M. This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, net revenue contribution from Optun...
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to exten...
Novocure enters clinical trial collab, supply agreement with Verastem
Novocure (NVCR) announced that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields therapy with chemo...
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of N...
Novocure receives approval for Optune Pax in Japan
Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, co...
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnose...
Novocure to Report Third Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management wi...
NovoCure Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Disciplined investment and cost controls have reignited GBM growth and enabled global expansion, with strong launches in pancreatic and lung cancer, especially in Japan. Profitability is within reach, and clinical trials are advancing, including new combination strategies with KRAS inhibitors.
NovoCure Transcript: Wells Fargo 21st Annual Healthcare Conference
Optune Pax's launch for pancreatic cancer exceeded expectations, with strong patient uptake and early payer coverage, while competitive therapies are not expected to significantly impact momentum. Expansion in Japan and Europe, pipeline progress, and disciplined financial management position the business for sustained growth.
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9...
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patient...
Novocure aware of unauthorized access to some information systems
In a regulatory filing, Novocure (NVCR) stated: “In mid-August 2026, NovoCure Limited through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the u...
Novocure price target raised to $20 from $18 at Wedbush
Wedbush raised the firm’s price target on Novocure (NVCR) to $20 from $18 and keeps a Neutral rating on the shares. The firm notes the company’s Q2 revenue of $183.6M…
Novocure price target raised to $52 from $46 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $52 from $46 and keeps a Buy rating on the shares. The company reported a record revenue quarter driven…